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Summary 
Background  
Trials of fluoxetine for recovery after stroke report conflicting results. The Assessment oF 
FluoxetINe In sTroke recoverY (AFFINITY) trial aimed to determine if daily fluoxetine for 6 
months after stroke improves functional recovery in Australasian and Vietnamese patients. 
  
Methods 
AFFINITY was a randomised, parallel-group, double-blind, placebo-controlled trial conducted 
in 43 hospital stroke units in Australia (n=29), New Zealand (4), and Vietnam (10).  Eligible 
patients were adults with a clinical diagnosis of stroke in the previous 2-15 days and a persisting 
neurological deficit. Patients were randomised via a web-based system using a minimisation 
algorithm to once daily, oral fluoxetine 20mg or matching placebo for 6 months. Patients, 
investigators and outcome assessors were masked to the treatment allocation. The primary 
outcome was functional recovery, measured by the modified Rankin scale (mRS), at 6 months. 
The primary analysis was an ordinal logistic regression of the mRS at 6 months, adjusted for 
minimisation variables. Analyses were according to the patient’s treatment allocation. The trial 
is registered with the ACTRN registry, number 12611000774921. 
  
Findings 
1280 patients were recruited in Australia (n=532), New Zealand (n=42) and Vietnam (n=706) 
between 11 January 2013 and 30 June 2019; 642 were allocated fluoxetine and 638 placebo. 
Adherence to trial medication (mean 167 [SD 48] days) was similar between groups. At 6 
months, mRS data were available in 624 (97.2%) patients allocated fluoxetine and 632 (99.1%) 
placebo. The distribution of mRS categories at 6 months was similar in the fluoxetine and 
placebo groups (adjusted common odds ratio 0.936, 95% CI 0.762-1.150; p=0.53), and 
consistent among all pre-defined subgroups. Compared to placebo, patients allocated 
fluoxetine had more falls (20 [3.12%] vs 7 [1.10%]; p=0.02), bone fractures (19 [2∙96%] vs 6 
[0.94%]; p=0.01) and epileptic seizures (10 [1.56%] vs 2 [0.31%]; p=0.04) at 6 months.  
Interpretation  
Fluoxetine 20mg daily for 6 months after acute stroke did not improve functional recovery and 
increased the risk of falls, bone fractures, and seizures. These results do not support the use, or 
further trials, of fluoxetine to improve recovery after stroke. 
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RESEARCH IN CONTEXT 
Evidence before this trial 
We undertook a Cochrane systematic review and searched Cochrane and clinical trial registers; 
MEDLINE, Embase, PubMed, and other biomedical databases; from their inception to 16 July 
2018; for randomised controlled trials (RCTs) that recruited stroke patients who had survived 
up to one year, and randomised them to a selective serotonin reuptake inhibitor (SSRI), at any 
dose, for any period, and any indication; or to usual care or placebo. We identified 63 RCTs 
that compared any SSRI with control in 9168 stroke survivors. About half of the trials required 
patients to have depression. Potential improvements in disability with fluoxetine were only 
present in trials at high risk of bias. A meta-analysis of the three trials at low risk of bias 
(n=3356 patients) found no effect of any SSRI compared to control on functional independence 
(risk ratio [RR] 1.00, 95% CI 0.91 to 1.09; p = 0.99) or disability score (standardised mean 
difference [SMD] -0.01, 95% CI -0.09 to 0.06; p = 0.75). The evidence before this trial suggests 
that SSRIs do not improve functional recovery after stroke, but doubt remains because this 
meta-analysis was dominated by one large trial, the FOCUS (Fluoxetine Or Control under 
Supervision) trial (n=3127), in UK patients. 
Added value of this trial 
The Assessment oF FluoxetINe In sTroke recoverY (AFFINITY) trial externally validates the 
the FOCUS trial and Cochrane systematic review of RCTs of SSRIs for stroke recovery in an 
independent population of Australasian and Vietnamese stroke patients, reinforcing the 
conclusion that fluoxetine does not improve functional recovery after stroke. The AFFINITY 
trial also adds further data regarding the potential hazards of treating acute stroke patients with 
fluoxetine 20 mg daily for 6 months, including increased risks of falls, fractures, and seizures. 
Implications of all the available evidence 
For clinicians, SSRIs should not be prescribed routinely to improve functional recovery after 
stroke because they are ineffective and increase serious adverse events. For researchers, a 
pooled analysis of individual patient data from completed RCTs of SSRIs for stroke recovery 
is needed to examine the effects of SSRIs in specific patient subgroups, such as those with 
hemiparesis, severe stroke, and cognitive impairment; and on specific outcomes, such as the 
mRS, motor domains of the Stroke Impact Scale, falls, fractures and seizures. Until these 
results are available, further trials of fluoxetine for stroke recovery are not recommended.  
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Introduction 
Stroke is the second leading cause of disability-adjusted life years globally.1,2 Fluoxetine, a 
selective serotonin re-uptake inhibitor (SSRI), may improve functional recovery and reduce 
disability after acute stroke. Fluoxetine exerts neuro-protective and neuro-regenerative effects 
in pre-clinical models of acute brain ischaemia.3,4 In the FLuoxetine for motor recovery After 
acute ischaeMic strokE (FLAME) trial, a double-blind, randomised controlled trial (RCT) in 
118 patients with acute ischaemic stroke and moderate to severe motor deficits, fluoxetine 20 
mg once daily significantly improved motor and functional recovery over 3 months.5 A 
subsequent Cochrane systematic review of 52 RCTs of SSRIs for stroke recovery in 4059 
patients concluded that SSRIs may improve disability but, given methodological limitations 
and heterogeneity of the available studies, more definitive, larger trials were required.6  
 
Hence, our international collaborative group designed and undertook three clinical trials of 
fluoxetine in the United Kingdom (Fluoxetine Or Control Under Supervision [FOCUS]), 
Sweden (Efficacy of Fluoxetine–A Randomised Controlled Trial in Stroke [EFFECTS]) and 
Australia, New Zealand and Vietnam (Assessment oF FluoxetINe In sTroke recoverY 
[AFFINITY]).7,8 The FOCUS trial (n=3127) reported that fluoxetine 20 mg given daily for 6 
months after stroke did not improve functional outcomes but reduced the occurrence of 
depression and increased the frequency of bone fractures.9 The results were consistent with 
reports of the effectiveness of fluoxetine as an antidepressant,10 and of an increased risk of 
fractures in older people taking SSRIs.11,12 However, as only two thirds of FOCUS trial patients 
took the trial medication for at least 150 of the prescribed 180 days, a modest, but important, 
effect of trial medication on functional outcome may have been missed.9 Moreover, as 96% of 
patients in FOCUS were white, the results may not be generalisable outside of the UK.9 Hence, 
the AFFINITY and EFFECTS trials continued to recruit patients in parallel until 30 June, 2019. 
 
Herein, we report results of the AFFINITY trial, which aimed to evaluate whether a 6-month 
course of fluoxetine is safe and effective, compared to placebo, for improving functional 
recovery after recent stroke in an ethnically diverse population. The results of the EFFECTS 
trial are reported in a parallel publication.13 
 
Methods 
Study design and participants 
6 
 
AFFINITY was a randomised, parallel group, double-blind, placebo-controlled clinical trial 
conducted in 43 hospital stroke units in Australia (n=29), New Zealand (4), and Vietnam (10). 
The trial protocol (appendix) was approved by the Royal Perth Hospital Ethics Committee on 
24 February, 2012 (approval number EC2011/131), and subsequent amendments to the 
protocol to facilitate trial recruitment were also approved. All participating sites received 
approval from their ethics committee and institutional review board. The trial protocol7 and 
statistical analysis plan8 were published before recruitment was completed.  
 
Eligible patients were adults (aged ≥18 years) with a clinical diagnosis of acute stroke within 
the previous 2-15 days, brain imaging consistent with ischaemic or haemorrhagic stroke 
(including a normal CT brain scan), and a persisting neurological deficit that produced a 
modified Rankin scale (mRS) score ≥1. Patients were excluded if there was any definite 
indication for fluoxetine (e.g. depression), or contraindication to fluoxetine (e.g. history of 
epilepsy, bipolar disorder, drug overdose, allergy to fluoxetine, or any recent medication that 
could interact with fluoxetine; or biochemical evidence of hepatic impairment [serum alanine 
aminotransferase (ALT)  > 120 U/l], renal impairment [creatinine > 180 µmol/l or estimated 
glomerular filtration rate (eGFR) < 30ml/min/1.73m2], or hyponatremia [sodium < 
125mmol/L]); if patients were unlikely to be available for follow-up during the subsequent 12 
months; if patients had another life-threatening illness that would make 12-month survival 
unlikely [e.g. terminal malignancy]; if patients were women and pregnant, breast-feeding or of 
child-bearing age without the use of contraception; or if patients were enrolled in another 
clinical trial of an investigational medicinal product or device.  
 
Written informed consent was obtained from each patient or, if the patients were unable to 
provide consent, from their legally approved surrogate.  
 
Randomisation and masking 
The patient’s clinician entered the patient’s baseline data (table 1) into a secure, password-
protected, centralised web-based randomisation system which checked the data for 
completeness and consistency and then generated a unique study identification number and 
treatment pack number which corresponded to fluoxetine or placebo in a 1:1 ratio. A 
minimisation algorithm14 was used to achieve balance between the treatment groups in four 
predictors of the primary outcome (mRS): time after stroke onset (2-8 vs 9-15 days), presence 
7 
 
of a motor deficit (National Institutes of Health Stroke Scale [NIHSS] questions 5 and 6), 
presence of aphasia (NIHSS question 9), and probability of survival free of dependency (mRS 
0-2) at 6 months (0.00 to ≤0∙15 vs >0∙15-1.00) as calculated using a previously validated 
prognostic model comprising six baseline prognostic variables (age, living alone before the 
stroke, independent in activities of daily living before the stroke, and able to talk, lift both arms 
off the bed, and walk unassisted at the time of randomisation).15 
 
All patients, carers, investigators, and outcome assessors were masked to the allocated treatment 
by use of placebo capsules that were visually identical to the fluoxetine capsules even when 
broken open. 
 
Procedures 
Fluoxetine 20mg capsules or matching placebo capsules were administered to patients orally, 
once daily, for 6 months. If the patient was unable to swallow, the capsules could be broken 
open and the contents administered via an enteral feeding tube.  
 
Siegfried Malta Ltd, Hal Far, Malta, manufactured the capsules containing fluoxetine 20mg 
according to Good Manufacturing Practice (certificate MT/008HM/2017). Arena 
Pharmaceuticals GmbH, Zofingen, Switzerland, packed the capsules for Amneal 
Pharmaceuticals Pty Ltd, South Yarra, Australia, which was the Therapeutic Goods 
Administration (TGA) licence holder (sponsor) for the finished product in Australia. 
Pharmaceutical packaging professionals (PPP) Pty Ltd, Port Melbourne, Australia purchased 
the fluoxetine capsules and manufactured the matching placebo capsules. PPP packaged the 
trial medication in patient kits, labelled the bottles with trial-specific treatment codes 
(fluoxetine or placebo), and packaged, stored and distributed the medication. The patient kits 
in Australian and New Zealand comprised two bottles, each containing 110 capsules, which 
were dispensed at randomisation and day 90. An extra 20 capsules were a reserve in the event 
of any delay in attending the day 90 follow-up, or any loss or spillage of capsules. For patients 
in Vietnam, the kits comprised 6 bottles of trial medication, each containing 35 capsules. One 
bottle was dispensed at randomisation, two bottles at day 28, and three bottles at day 90. The 
TGA of the Australian government’s Department of Health approved the export of trial 
medication to New Zealand and Vietnam (approval Ref No: EX17/336513). 
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All patients received organised, interdisciplinary care and rehabilitation in stroke units. 
 
Patients recruited in Australia and New Zealand were assessed by site investigators at 28 days 
(1 month) and 90 days (3 months) post-randomisation in the hospital ward or outpatient clinic 
or via telephone or email; or, failing that, by a study nurse at the patient’s residence. Follow-
up at 180 days (6 months) was by postal questionnaire or telephone by trained staff in the trial 
coordinating centre in Perth, Australia. Patients recruited in Vietnam were assessed by the site 
investigator at 28, 90 and 180 days post-randomisation in the hospital ward or outpatient clinic, 
or via telephone or email; or, failing that, at the patient’s residence. If the patient was unable 
to complete the assessments, assistance was sought from their proxy (next of kin, close family 
member or carer). Each assessment recorded the primary outcome (mRS), secondary outcomes 
(table 2), safety and adverse events (table 3), all current medications, and adherence to trial 
medication. Serum sodium, eGFR, and liver function were measured at the first (28 day) 
follow-up visit if clinically appropriate. Adherence to trial medication was assessed by asking: 
‘On average, since the last follow-up, how many times per week was the trial medication taken? 
‘0, 1-2, 3-4, 5-6 or 7 times per week’; and by pill counts and collection of returned trial bottles. 
Bottle and pill counts were conducted by hospital trial pharmacists, and entered on a drug 
accountability form. Any interruption to trial medication was recorded as temporary or 
permanent, together with the dates and reasons for stopping and re-starting.  
 
If patients developed new depression requiring treatment during the trial treatment period, the 
protocol recommended continuation of trial medication and consideration of non-
pharmacological (e.g. psychological) interventions. If antidepressant medication was 
considered necessary, referral to a psychiatrist was recommended for consideration of potential 
interactions of any new medication with fluoxetine and risks of serotonin toxicity.  
 
There were 57 protocol violations in 56 patients (4.4%): 20 (1.6%) patients were prescribed 
open-label fluoxetine; 8 (0.6%) were prescribed another SSRI; 16 (1.3%) lost their trial 
medication or did not take the trial medication as prescribed; 4 (0.3%) took medications that 
could interact with fluoxetine (e.g. antipsychotic, tramadol); 7 (0.5%) patients were more than 
14 days late for a scheduled follow-up; one patient enrolled in another trial was deemed 
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ineligible, and four patients had a final diagnosis other than stroke  (table 1). Emergency 
unblinding was not necessary for any patient.  
 
Outcomes 
The primary outcome was functional status, as measured by the mRS, at 6 months after 
randomization.16 The mRS is an ordinal scale which assigns patients to seven ordered, but not 
equally spaced, levels of functional ability, ranging from 0 (symptom free) to 6 (dead).  
 
Secondary outcomes at 6 months were survival, depression (PHQ-9 score > 1517), cognition 
(Telephone Interview for Cognitive Status [TICSm]18), communication, motor function, 
overall health status (Stroke Impact Scale [SIS] version 3.019), fatigue (vitality subscale of the 
SF-3620,21) and health-related quality of life (HRQoL) using the EQ-5D-5L.22 A new diagnosis 
of depression requiring treatment with antidepressants was assessed at 1, 3 and 6 months by 
asking patients if they had been diagnosed with depression since each of their previous 
assessments, and verifying the diagnosis and treatment plan with their clinician. 
 
Serious adverse events at any time during follow-up included recurrent stroke (ischaemic or 
haemorrhagic), acute coronary syndromes, upper gastrointestinal bleeding requiring blood 
transfusion and/or endoscopy, other major bleeding (subdural, extradural, ocular, lower 
gastrointestinal) requiring blood transfusion or procedural intervention, falls with injury, new 
bone fractures, epileptic seizures, symptomatic hypoglycaemia (blood glucose < 3mmol/l), 
symptomatic hyperglycaemia (blood glucose > 22mmol/l), new hyponatraemia (blood sodium  
< 125mmol/l), attempted suicide or self-harm, and death. 
 
Statistical analysis 
A detailed statistical analysis plan was formulated and published before recruitment was 
completed and without awareness of any unblinded data.8 
 
We estimated from other concurrent studies of patients with acute stroke that 42.2% of patients 
assigned placebo would be functionally independent (mRS 0-2) at 6 months after 
randomisation.23,24 We calculated the odds ratio (OR) of functional independence (mRS 0-2) 
with fluoxetine vs placebo in the FLAME study5 to be 3.57 (95%CI: 1.2 to 10.6). We 
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considered a conservative estimate of the effect of fluoxetine may be toward the lower 95% CI 
of the OR estimate reported in FLAME (e.g. OR 1.34). If fluoxetine increased the proportion 
of patients who were functionally independent at 6 months by an OR of 1.34, from 42.2% 
(placebo) to 49.4% (fluoxetine), this would be clinically important and consistent with our 
Cochrane review6 – that is, a 7.2% absolute increase in functional independence in patients 
allocated fluoxetine compared with placebo. Assuming a common OR of 1.34 for each cut-
point across the mRS (e.g. 0 vs 1-6, 0-1 vs 2-6, etc) in the proportional odds logistic model, we 
estimated that the trial would require 1600 patients to have 90% power, if up to 10% of patients 
dropped out before final follow-up.8,25  
 
All analyses, including primary and secondary outcomes and adverse events, were by intention-
to-treat, according to the treatment allocation. A secondary safety analysis was undertaken 
according to the treatment patients received rather than what they were randomly allocated. 
 
The primary analysis was an ordinal analysis of the mRS scores at 6 months in each treatment 
group using ordinal logistic regression and after adjusting for the baseline factors included in 
the minimisation algorithm.8 The ordinal analysis of mRS was undertaken by treatment 
allocation, under the assumption of proportional odds in the model. The result was expressed 
as a common OR (less than 1.0 favoured placebo) and its 95% confidence interval (CI). We 
also performed 6 binary unadjusted logistic regressions, each corresponding to the 6 possible 
dichotomisations of scores on the mRS.  
 
Secondary analyses compared the following outcomes at 6 months follow-up in each treatment 
group: survival, depression (changes in PHQ-9 scores and proportion with PHQ-9 ≥ 15 ),17 
cognition (TICSm scores),18 communication (SIS),19 motor function (SIS),19 overall health 
status (SIS),19 HRQoL (EQ-5D-5L),22 new diagnosis of depression requiring treatment with 
antidepressants, fatigue (vitality domain of the SF-36)20,212, trial medication adherence and 
cessation, and serious adverse events. The frequencies of categorical outcome events, including 
adverse events, in each treatment group were compared using Fisher’s exact test. For 
continuous outcomes, the mean or median in each group, depending on the distribution, were 
calculated with measures of dispersion (standard deviation [SD] or inter-quartile range [IQR]). 
The probability that outcome measures in the treatment group were significantly different from 
those observed in the placebo group were calculated and expressed as p-values.   
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Pre-specified subgroup analyses of the effect of fluoxetine vs placebo on the primary outcome 
were undertaken for key baseline variables, including country of randomisation (Australia/New 
Zealand vs Vietnam), age (<70 vs >70 years), time from stroke onset to randomisation (2-8 vs 
9-15 days), stroke pathology (ischaemic vs haemorrhagic), stroke severity (NIHSS scores 0-5 
vs >5), motor deficit (present vs absent), aphasia (present vs absent), probability of survival 
free of dependency (0.00 to <0.15 vs >0.15 to 1.00), self-reported depression at baseline, and 
source of informed consent.8  
 
We also undertook pre-specified per-protocol analyses, which sequentially excluded subgroups 
of patients who did not meet our eligibility criteria or had incomplete adherence to the trial 
medication. 
 
Post-hoc sensitivity analyses of the primary outcome were undertaken to evaluate the possible 
effect of including those patients who were lost to follow-up. We tested the robustness of the 
results by assuming two extreme imputation scenarios: one favouring fluoxetine where all 
patients with a missing mRS were imputed a score of 0 in the fluoxetine arm and a score of 6 
in the placebo arm, and another scenario favoring placebo where the imputation was reversed. 
 
Statistical analyses were undertaken with SAS, version 9.4 
 
An independent data monitoring committee (DMC) oversaw the study. The unmasked trial 
statistician (Q Yi) prepared analyses of the accumulating data, which the DMC reviewed in 
strict confidence at least once a year. 
 
The trial is registered with the Australian New Zealand Clinical Trials Registry, number 
ACTRN12611000774921. 
 
Role of the funding source 
The funder of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding author had full access to all the data 
in the study and had final responsibility for the decision to submit for publication. 
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Results 
A total of 1280 patients consented and were randomised at 43 sites in Australia, New Zealand 
and Vietnam between 11 January, 2013 and 30 June, 2019. Recruitment was terminated before 
the target sample size of 1600 patients was reached as grant funding expired on 31 December 
2019.  
642 patients were randomly allocated to fluoxetine and 638 to placebo. One patient did not 
meet our eligibility criteria after randomisation because of later discovery of participation in 
another clinical trial of an investigational medicinal product. In four patients, the initial 
diagnosis was revised to be non-stroke after review of investigations at the one month follow 
up (table 1).  
Baseline characteristics in the two treatment groups were balanced (table 1)  
By 6 months, 22 (1.7%) patients had withdrawn consent for follow-up and a further 2 (0.2%) 
patients were lost to follow-up (fig 1). There was no difference in the methods of follow-up 
between treatment groups (appendix table 1, p8). Trial medication was started in 1273 patients, 
and it was temporarily and permanently stopped in 158 and 208 patients respectively, before 
the 6-month follow-up (appendix, table 2, p9). There was no significant difference between 
treatment groups in temporary and permanent discontinuation of trial medication (appendix 
table 2, p9) or time to permanent discontinuation (p=0.75; appendix figure 1, p14). There were 
also no significant differences between groups in compliance with trial medication at one 
(p=0.57), three (p=0.94) or six (p=0.92) months (appendix table 3, p10). The mean duration of 
trial treatment during the 6 months follow-up was 167 days (SD 48.1) days.  
The primary outcome, the mRS at 6 months, was assessed and analysed in 624 (97.2%) patients 
allocated fluoxetine and 632 (99.1%) placebo. An ordinal comparison of the distribution of 
patients across the mRS categories at 6 months, adjusted for variables included in the 
minimisation algorithm, was similar in the two groups (common OR 0.936, 95% CI 0.762-
1.150; p=0.53; figure 2). A common OR <1.0 favours placebo. The unadjusted analysis 
produced similar results (common OR 0.966, 95%CI 0.790-1.181; p=0.74; appendix table 4, 
p11). The assumption of proportional odds in the model of mRS by treatment was upheld in 
the score test for proportional odds assumption (p=0.44 unadjusted). Comparison of 
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dichotomised mRS scores (0–2 vs 3–6) also showed no significant difference between 
treatment groups (unadjusted OR 0.855, 95%CI 0.670-1.091; p=0.21; post-hoc adjusted 
OR=0.823, 0.628-1.077; p=0.16; appendix table 4, p11). There was also no difference between 
groups in other dichotomies of the mRS (appendix table 4, p11). 
Analysis of the primary outcome showed no significant interactions or modification of the 
effect of fluoxetine across several pre-specified subgroups (appendix figure 2, p15).  
Secondary efficacy outcome measures at 6 months are shown in table 2. Patients allocated 
fluoxetine had better mood and emotional control, as measured by higher scores in the SIS 
domain of mood/emotions compared to placebo (p=0.003), but there were no significant 
differences between treatment groups in the other 10 domains of the SIS (including measures 
of motor function [strength, hand ability, mobility] and daily activities), other assessment 
scales, or death. There was a reduction in new diagnoses of post-stroke depression which was 
not statistically significant (33 [5.14%] fluoxetine vs 46 [7.21%] placebo; absolute risk 
difference 2.07%; 95% CI -0.57% to 4.41%]). 
Adverse events at 6 months are shown in table 3. Compared to patients allocated placebo, those 
allocated fluoxetine had more falls causing injury (20 [3.12%] vs 7 [1.10%]; difference 2.02% 
[95CI: 0.45-3.59]; p=0.02), bone fractures (19 [2∙96%] vs 6 [0.94%]; difference 2.02% [0∙51–
3.53]; p=0∙01) and epileptic seizures (10 [1.56%] vs 2 [0.31%]; difference 1.24% [0.19-2.30]; 
p=0.04). There were no significant differences between treatment groups in other events at, or 
during, the 6 months follow-up, including survival (p = 0.71, appendix, figure 3, p16). Trial 
medication was stopped by 68 patients (27 allocated fluoxetine, 41 placebo) due to a suspected 
adverse reaction to the medication. No patients required a reduction in dose of trial medication 
(e.g. alternate daily) and there were no treatment-related deaths. 
The primary results were not altered by sensitivity analyses confined to patients who adhered 
to the trial protocol and allocated treatment (appendix table 5, p12).  
A post-hoc analysis, which consisted of imputing missing mRS data under two extreme 
scenarios, also produced consistent, non-significant results for the most extreme scenario in 
favour of fluoxetine (unadjusted OR 1.082, 95%CI 0.887-1.320; p=0.44; adjusted OR 1.054, 
0.861-1.291; p=0.61), and for the most extreme scenario in favour of placebo (unadjusted OR 
0.860, 0.705-1.050; p=0.14; adjusted OR 0.833, 0.680-1.020; p=0.09). 
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Discussion 
The main finding of the AFFINITY trial was that adding fluoxetine 20mg daily for 6 months 
after acute stroke to interdisciplinary stroke unit care did not improve functional outcome at 6 
months in an ethnically diverse population. Other major findings were that fluoxetine improved 
mood and emotional control but increased falls, fractures, and epileptic seizures at 6 months. 
 
Key strengths of the trial are that it was undertaken in stroke units throughout Australia, New 
Zealand and Vietnam where the AFFINITY trial medication was added to best-practice, 
comprehensive interdisciplinary stroke care and rehabilitation. Several potential sources of 
systematic error (bias) in the assessment of fluoxetine vs placebo were minimised. Systematic 
pre-treatment differences in comparator groups (selection bias) were minimised by concealed, 
central, web-based randomisation. Adherence to trial medication was high and similar between 
treatment groups (performance bias). Systematic differences between groups in other care 
provided (performance bias) and reporting and assessment of outcome events (observer 
detection bias) were minimised by masking of patients, investigators and adjudicators to the 
allocated treatment. Follow up for the primary outcome was high and there was no difference 
between groups in withdrawals from treatment (attrition bias). Random error was reduced to 
some extent by almost complete follow-up of a large number of patients (n=1256, 98%), which 
was a higher proportion than planned in our sample size calculations (90% of 1600; n=1440). 
The inclusion of an international mix of ethnic groups managed in different health care systems, 
and a comprehensive array of secondary outcome measures, including cognition, mood and 
motor scales, support the external validity (generalisability) of the trial results. 
 
Potential limitations of the trial include our failure to recruit the target sample size of 1600 
patients due to funding constraints (1280 patients recruited; 1256 with primary outcome data 
vs 1440 planned to have primary outcome data). We also failed to recruit a larger number of 
patients with severe, disabling stroke. Hence, the proportion of patients assigned placebo who 
recovered functional independence (mRS 0-2) at 6 months was higher (n=458, 72%) than 
estimated in our sample size calculations (42%). The dose of fluoxetine was 20 mg once daily 
because this was the dose reported to be effective in the FLAME trial5 and used in other 
fluoxetine trials for stroke recovery,6 and is less likely to cause adverse effects than higher 
doses. However, we did not test higher doses of fluoxetine. Our measures of adherence to trial 
medication by self-report and capsule-counting were prone to error (e.g. the absence of tablets 
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in the bottles returned to investigators may not necessarily mean adherence to taking the 
tablets) and therefore, our estimates of adherence and compliance may be inflated. However, 
there was no difference between groups in reported adherence to, and discontinuation of, trial 
medication. The nature and degree of adjunctive rehabilitation was not documented because 
that would have added complexity and potential measurement error to this pragmatic trial. 
However, all patients were admitted to stroke units where organised interdisciplinary 
assessment, and rehabilitation as required, was provided as standard practice. The nature and 
intensity of all rehabilitation interventions were likely to be balanced between the treatment 
groups, in the same way that all baseline variables were balanced between groups, due to the 
randomisation process and double-blind trial treatment allocation. There was a slight difference 
in ascertainment of mRS status at 6 months between groups (fluoxetine n=624, 97.2% vs 
placebo n=632, 99.0%) but sensitivity analyses using imputations led to consistent conclusions. 
Our primary measure of efficacy was a broad measure of functional outcome which may not 
be sensitive to changes in measures of specific neurological functions, However, we also 
measured 11 domains of the SIS, including measures of motor function (strength, hand ability, 
mobility), physical function, and daily activities, and found no effect of fluoxetine on any of 
these measures. The mRS may be less sensitive to change in patients with less severe stroke 
but there was no evidence of an effect of fluoxetine on the mRS in patients with more severe 
stroke (NIHSS > 5; appendix figure 2, p15), and no effect of fluoxetine on any secondary 
outcome except mood and emotional control. 
 
The AFFINITY trial was smaller than the FOCUS trial9 but both trials recruited patients of 
similar stroke severity (median NIHSS=6) and at a similar time (one week, mean) after stroke 
onset. The AFFINITY trial population was a unique mix of Vietnamese (n=727, 57%) and 
Australasians (n=553, 43%), whereas the FOCUS population was predominantly Caucasian 
(n=2988; 96%). Patients in AFFINITY were also younger (mean age 64 years AFFINITY, vs 
71 years in FOCUS), and more likely to be married (n=926, 72% vs n=1725, 55%), living with 
someone else (n=1120, 87% vs n=2091, 67%), employed (n=531, 41% vs n=691, 22%), and 
independent before their stroke (n=1264, 99% vs n=2866, 92%) compared to FOCUS. 
Adherence to trial medication was higher in AFFINITY than FOCUS; 34 (5.4%) patients 
assigned fluoxetine and 30 (4.8%) placebo stopped trial medication within the first 90 days, 
whereas in FOCUS, 143 (9%) patients assigned fluoxetine and 122 (8%) placebo stopped trial 
medication within the first 90 days. Despite these differences, the results of the AFFINITY 
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trial almost replicate those of the larger FOCUS trial,9 supporting the internal and external 
validity of both trials. Furthermore, the EFFECTS trial of fluoxetine vs placebo in 1500 stroke 
patients in Sweden also reports very similar results to FOCUS and AFFINITY.13 Moreover, 
the results of the FOCUS, AFFINITY and EFFECTS trials are all consistent with the totality 
of evidence from all RCTs of SSRIs for stroke recovery,26 and all RCTs specifically testing 
fluoxetine.27 Collectively, these trials provided compelling evidence that fluoxetine does not 
improve functional recovery after stroke.  
 
The outstanding inconsistency among all the RCT evidence is the FLAME trial, which did 
report a significant benefit of fluoxetine vs placebo on functional recovery measured by the 
mRS.5 The FLAME trial differed from AFFINITY, FOCUS and EFFECTS in that it was a 
phase II trial of fluoxetine 20 mg daily vs placebo in a highly select population of 113 patients 
with a moderate to severe hemiparesis or hemiplegia, defined by a Fugl-Meyer motor scale 
(FMMS) score <55.5 The FMMS motor score ranges from 0 (hemiplegia) to a maximum of 
100 points (normal motor performance), divided into 66 points for the upper extremity and 34 
points for the lower extremity. At baseline, there was some imbalance between the treatment 
groups; the mean total FMMS score was higher (better motor performance) in the fluoxetine 
group (17·1; SD 11·7) than placebo group (13·4; SD 8·8), and the mean total NIHSS was 
marginally lower (less severe stroke) in the fluoxetine group (12·8; SD 3·9) than placebo group 
(13·1; SD 4·3).5 Somatosensory and other neurological deficits that may influence recovery 
were not reported. The primary outcome measure, the mean change in FMMS scores between 
randomisation and day 90, was greater with fluoxetine than placebo (34·0 points fluoxetine vs 
24·3 points placebo; difference 9.8 points, 95%CI: 3.4 to 16.1, p=0·003). The proportion of 
functionally independent patients (mRS scores 0-2) at day 90 was also higher with fluoxetine 
than placebo (n=15, 26% vs n=5, 9%; p=0.02). The FLAME trial result may be a false-positive 
due to random error (chance), as only 57 patients were treated with fluoxetine and followed-
up to 90 days,5 and there is large variation in spontaneous motor recovery after acute stroke.28 
Alternatively, the FLAME trial result may a true-positive, and fluoxetine may indeed improve 
recovery of motor function in patients with severe motor impairment. The AFFINITY trial did 
not include a large number patients with severe hemiparesis and did not measure motor 
recovery by the FMMS, but did measure motor functions as domains within the SIS and found 
no effect of fluoxetine. Our planned individual patient data meta-analysis of the FOCUS, 
AFFINITY and EFFECTS trials8 will constitute a larger number of stroke patients with severe 
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motor impairments and promises to enable a more reliable analysis of the effect of fluoxetine, 
vs placebo, on the mRS and motor domains of the SIS at 6 months in this subgroup. 
 
The AFFINITY trial also confirms the FOCUS trial finding that long-term fluoxetine in stroke 
patients has hazards, increasing the risk of bone fractures.9 We also found that fluoxetine 
significantly increased the risk of falls with injury and epileptic seizures in stroke patients. 
These hazards of fluoxetine were sought apriori during patient follow-up.7,8 The FOCUS trial 
reported similar, but not significant, increases in falls with injury and seizures in patients 
allocated fluoxetine.9 The AFFINITY and FOCUS trials collectively provide robust evidence 
about the effect of an SSRI on the incidence of falls causing injury, and fractures, increasing 
the absolute risk of each by about 2% over 6 months among patients with recent stroke. 
 
Although fluoxetine is more effective than placebo in treating major depressive disorders,10 
and reduced the rate of new depression in the FOCUS,9 and other trials,27,29 we observed only 
improved mood and emotional control, as measured by the SIS, at 6 months with fluoxetine; 
the numerically lower rate of post-stroke depression with fluoxetine vs placebo was not 
statistically significant. We believe we lacked statistical power to show a significant effect of 
fluoxetine on post-stroke depression because the absolute rates of depression in both groups in 
AFFINITY were substantially lower (less than half) than in FOCUS, possibly from under-
reporting, particularly in Vietnam where the reporting of changes in mood may be affected by 
the cultural setting.30 
 
In summary, the AFFINITY trial reinforces the conclusion of a recent Cochrane review that 
SSRIs are not effective at improving functional recovery after stroke. It also confirms that 
fluoxetine may improve mood but have important adverse effects, particularly bone fractures. 
A planned individual patient data meta-analysis of the AFFINITY, FOCUS and EFFECTS 
trials will produce greater precision in the estimates of the effects of fluoxetine on recovery in 
important patient subgroups.8 
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1280 consented and randomly 
assigned 
642 assigned to fluoxetine group 
 637 received fluoxetine 
 5      did not receive fluoxetine  
        (medication was lost after discharge; 
        family’s/patient’s decision to not start) 
 
638 assigned to placebo group 
 635 received placebo 
 2     did not receive placebo  
(family’s/patient’s decision to not start; 
ineligible [randomising event was a TIA]) 
 
621 submitted 180-day 
form 
 100  discontinued 
placebo 
 632  had mRS data 
available 
30 did not submit 180-day 
form 
 12   died 
 17 withdrew consent 
 1     too late (>14 days)    
17 did not submit 180-day 
form 
 11  died 
 5    withdrew consent 
 1    too late (>14 days)    
 
642 analysed 
 624 analysed for mRS  
(mRS not available for 18) 
612 submitted 180-day 
form 
 108  discontinued 
fluoxetine 
 624  had mRS data 
available  
638 analysed  
 632 analysed for mRS  
(mRS not available for 6)  
Allocation 
 
Follow-Up 
 
Analysis 
 
Enrolment 
Figure 1: AFFINITY trial profile     mRS=modified Rankin Scale 
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Figure 2.  
Primary outcome of the distribution of the modified Rankin Scale (mRS) scores at 6 
months by treatment group. 
The primary outcome was an assessment of scores across all seven categories of the mRS 
(ranging from 0 [no symptoms] to 6 [death]), using a shift analysis of the ordinal data. The 
odds ratio and p-values were calculated with ordinal logistic regression, adjusted for the 
baseline variables included in the minimisation algorithm (delay between stroke onset and 
randomization, probability of being alive and independent at 6 months, presence of a motor 
deficit, presence of aphasia). mRS data at 6 months were available for 624 (97.2%) patients 
allocated fluoxetine and 632 (99.1%) allocated placebo. The common odds ratio was 0.936 
(95%CI: 0.762 to 1.150), p= 0.53; adjusted for baseline minimization variables. A common 
OR less than 1.0 favoured placebo. 
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Table 1. Patient characteristics at randomization by allocated treatment 
 Fluoxetine 
(n=642) 
Placebo 
(n=638) 
   
Sex   
Women    231 (36%) 245 (38%) 
Men 411 (64% ) 393 (62% ) 
Age   
Age < 70 years 450 (70% ) 432 (68% ) 
Age >70 years 192 (30% ) 206 (32% ) 
Mean age, years 63.5 (12.5 ) 64.6 (12.2 ) 
Ethnicity   
Asian 356 (55% ) 371 (58% ) 
White  267 (42% ) 255 (40% ) 
Other 19 (3% ) 12 (2%) 
Marital status   
Married 463 (72% ) 463 (73% ) 
Partner 29 (4% ) 19 (3% ) 
Divorced or separated 37 (6% ) 46 (7% ) 
Widowed 61 (9% ) 70 (11% ) 
Single 52 (8% ) 38 (6% ) 
Other 0 (0% ) 2 (0% ) 
Living arrangements   
Living with someone else 564 (88% ) 556 (87% ) 
Living alone 78 (12% ) 78 (12% ) 
Living in an institution 0 (0% ) 2 (0% ) 
Other 0 (0% ) 2 (0% ) 
Employment status   
Full-time employment 206 (32% ) 180 (28% ) 
Part-time employment 77 (12% ) 68 (11% ) 
Retired 315 (49% ) 363 (57% ) 
Unemployed or disabled 24 (4% ) 14 (2% ) 
Other  20 (3% ) 13 (2% ) 
Independent before stroke 634 (99% ) 630 (99% ) 
Previous medical history   
Coronary Heart Disease 58 (9% ) 57 (9% ) 
Ischaemic stroke or TIA  77 (12% ) 84 (13% ) 
Diabetes 143 (23% ) 147 (23% ) 
Hyponatraemia 1 (0% ) 3 (0% ) 
Intracranial bleed 11 (2% ) 8 (1% ) 
Upper gastrointestinal bleed 11 (2% ) 15 (2% ) 
Bone fractures 71 (11% ) 74 (12% ) 
Depression 30 (5% ) 20 (3% ) 
Stroke diagnosis   
Non-stroke (final diagnosis) 3 (0% ) 1 (0% ) 
Ischaemic stroke 549 (86% ) 542 (85% ) 
Tables
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Intracerebral haemorrhage 90 (14% ) 95 (15% ) 
OCSP classification of Ischaemic stroke   
Total anterior circulation infarct  47 (9% ) 50 (9% ) 
Partial anterior circulation infarct  271 (49% ) 283 (52%) 
Lacunar infarct 115 (21% ) 105 (19% ) 
Posterior circulation infarct 114 (21% ) 103 (19%) 
Uncertain 2 (0% ) 1 (0% ) 
Causes of ischaemic stroke (modified 
TOAST classification) 
  
Large artery disease 123 (22% ) 134 (25% ) 
Small vessel disease 261 (47%) 250 (46%) 
Embolism from the heart 95 (17%) 93 (17%) 
Another cause 9 (2%) 8 (1%) 
Unknown or uncertain cause 61 (11%) 57 (10%) 
Predictive variables    
Able to walk at time of randomisation 282 (44%) 279 (44%) 
Able to lift both arms off bed 443 (69%) 431 (68%) 
Able to talk and not confused 554 (86%) 557 (87%) 
Predicted 6-month outcome based on 
SSV 
  
Probability of being alive and 
independent 
0.57 
(0.26-0.87) 
0.55 
(0.24-0.87) 
0.00 to < 0.15 100 (15%) 103 (16%) 
0.15 to 1.00 542 (84%) 535 (84%) 
Neurological deficits   
NIHSS 6 (3-9) 6. (3-9) 
Presence of a motor deficit 557 (87%) 548 (86%) 
Presence of aphasia 129 (20%) 121 (19%) 
Depression at baseline   
Current diagnosis of depression (patient 
or proxy reported) 
15 (2%) 17 (3%) 
Taking a non-SSRI antidepressant 5 (1%) 5 (1%) 
Current mood   
PHQ-9, median (IQR)           4 (1-7) 4 (2-7) 
0-14 601 (98%) 596 (98%) 
>15 12 (2%) 11 (2%) 
Delay (days) since stroke onset at 
randomisation 
  
Mean delay  6.1 (3%) 6.3 (3%) 
2-8 days 486 (76%) 479 (75%) 
9-15 days 156 (24%) 159 (25%) 
Consent   
Patient consented  345 (54%) 328 (51%) 
Person responsible consented 284 (44%) 295 (46%) 
Proxy consented 3 (0%) 1 (0%) 
Waiver acknowledgement 10 (2%) 14 (2%) 
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Data are n (%), mean (SD [standard deviation]), or median (IQR [interquartile range]) 
TIA: transient ischaemic attack 
OCSP = Oxfordshire Community Stroke Project 
TOAST = modified Trial of ORG 10172 in acute stroke treatment criteria 
SSV = Six simple variables the predict functional outcome, as measured by the mRS, after 
stroke (age, living alone before the stroke, independent in activities of daily living before the 
stroke, and able to talk, lift both arms off the bed, and walk unassisted at the time of 
randomisation).15 
NIHSS = National Institutes of Health Research Stroke Scale 
SSRI: selective serotonin reuptake inhibitor 
PHQ-9 = Patient Health Questionnaire 9 items (higher scores indicate more depressive 
symptoms).17 
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Table 2.  Secondary outcomes at six months by allocated treatment  
  Fluoxetine (n=642)  Placebo (n=638)  P value 
New depression  
   N / N (%) 
33 (5.1%)  46 (7.2%)  0.13 
Mood (PHQ-9) 2.0 (1.0-5.0 ) 2.0 (1.0-5.0 ) 0.42 
   PHQ-9 >15   
   N / N% 
4 (0.7%)  6 (1.0%)  0.75 
Cognition (TICSm) 24.0 (20.0 -27.0 ) 24.0 (19.0-27.0 ) 0.62 
Stroke Impact Scale 
(SIS) domains 
     
-Strength 75.0 (56.3-93.8 ) 75.0 (56.3-93.8 ) 0.26 
-Hand ability 85.0 (55.0-100.0 ) 85.0 (55.0-100.0 ) 0.39 
-Mobility 91.7 (69.4-100.0 ) 88.9 (66.7-97.2 ) 0.08 
-Motor†  83.5 (63.5-94.2 ) 82.4 (60.4-93.2 ) 0.28 
-Daily Activities 90.0 (72.5-100.0 ) 90.0 (70.0-97.5 ) 0.25 
-Physical function‡ 85.5 (66.2-94.9 ) 83.8 (63.4-93.8 ) 0.24 
-Memory 89.3 (78.6-100.0 ) 89.3 (75.0-100.0 ) 0.28 
-Communication 98.2 (89.3-100.0 ) 96.4 (85.7-100.0 ) 0.61 
-Mood/Emotions^ 80.6 (66.7 -88.9 ) 77.8 (66.7 -86.1 ) 0.003 
-Participation 81.3 (59.4 -96.9 ) 75.0 (56.3 -96.9 ) 0.48 
-Recovery (VAS) 80.0 (60.0 -90.0 ) 80.0 (60.0 -90.0 ) 0.90 
Vitality (SF-36) 70.0 (55.0 -80.0 ) 70.0 (55.0 -80.0 ) 0.36 
EQ5D-5L  0.81 0.63-1.00 0.78 0.58-0.93 0.08 
 
Data were only available for those who survived and who completed sufficient questions to derive a 
score. The number of patients with missing scores were similar in the two treatment groups. 
Data are median (IQR). 
PHQ-9: Patient Health Questionnaire 9 items (higher score indicates more depressive symptoms) 
TICSm:  Telephone Interview for Cognitive Status  
SIS: Stroke Impact Scale (where higher scores are better).      
†Mean of the Strength, Hand ability, and Mobility domains.  
‡Mean of the Strength, Hand ability, Mobility, and Daily activities domains. 
^Mood/Emotions domain of the SIS: Nine questions about “how you feel, changes in your mood, and 
your ability to control your emotions, since your stroke.” (where higher scores are better) 
VAS: visual analogue scale. 
SF-36: 36 item short form questionnaire (higher scores indicate less disability) 
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EQ5D-5L:  EuroQoL - 5 Dimensions (Mobility, Personal Care, Usual Activities, Pain/Discomfort, 
Anxiety/Depression) - 5 Levels (where 1 indicates the best health imaginable, and −0.676 indicates 
the worst health imaginable).  
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Table 3.  Adverse events at 6 months by allocated treatment group 
   
  Fluoxetine 
(n=642) 
Placebo 
(n=638) 
Difference (95% CI)* P-
value 
 
Death 15 (2.34%) 15 (2.35%) 0.01% (-1.64 to 1.67) 1.00 
Any stroke 18 (2.80%) 26 (4.08%) -1.27% (-3.27 to 0.72) 0.22 
All thrombotic events     
   Ischaemic stroke 11 (1.71%) 21 (3.29%) -1.58% (-3.29 to 0.13) 0.08 
   Acute coronary events 1 (0.16%) 2 (0.31%) -0.16% (-0.69 to 0.37) 0.62 
All bleeding events     
   Haemorrhagic stroke 3 (0.47%) 1 (0.16%)  0.31% (-0.30 to 0.92) 0.62 
   Upper gastrointestinal bleed 1 (0.16%) 1 (0.16%) 0.00% (-0.43 to 0.43) 1.00 
Epileptic seizures 10 (1.56%) 2 (0.31%) 1.24% (0.19 to 2.30) 0.04 
Fall with injury 20 (3.12%) 7 (1.10%) 2.02% (0.45 to 3.59) 0.02 
New bone fracture 19 (2.96%) 6 (0.94%) 2.02% (0.51 to 3.53) 0.01 
Hyponatraemia < 125mmol/l 3 (0.47%) 2 (0.31%) 0.15% (-0.53 to 0.84) 1.00 
Hyperglycaemia 0 (0%) 0 (0%) 0%  
Symptomatic hypoglycaemia 0 (0%) 0 (0%) 0%  
New depression 33 (5.14%) 46 (7.21%) -2.07% (-4.71 to 0.57) 0.13 
New antidepressant 30 (4.67%) 43 (6.74%) -2.07% (-4.61 to 0.47) 0.12 
Attempted or actual suicide 0 (0%) 2 (0.31%) -0.16% (-0.75 to 0.12) 0.25 
Other adverse event  62 (9.66%) 68 (10.66%) -1.00% (-4.31 to 2.31) 0.56 
 
Data are n (%), unless otherwise stated 
 
* Risk differences and their 95%confidence intervals were calculated in SAS  by 
means of the FREQ procedure.    
https://documentation.sas.com/?docsetId=procstat&docsetTarget=procstat_freq_detail
s54.htm&docsetVersion=9.4&locale=en (accessed March 18, 2020). The confidence 
intervals around the risk differences are Wald intervals based on the normal 
approximation. 
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National coordinators 
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Huy Thang-Nguyen, The People's Hospital 115, Neurology, Ho Chi Min City, Vietnam 
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John Gommans 
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Packaged by Amneal Pharmaceuticals Pty Ltd (Australian Therapeutic Goods Administration 
[TGA] licence holder). 
Re-packaged (as patient kits, two bottles, each containing 110 capsules), labelled (with trial-
specific treatment codes, fluoxetine or placebo), and distributed by PPP Pty Ltd. 
Export to New Zealand and Vietnam approved by the Australian Government Department of 
Health TGA (Approval Ref No: EX17/336513). 
 
Funding 
National Health and Medical Research Council, Australia 
 
Registration  
Australian New Zealand Clinical Trial Registry number: ACTRN12611000774921 
 
Sponsors 
Royal Perth Hospital and Sir Charles Gairdner Hospital, Perth, Western Australia 
 
Participating centres and number of patients randomised in each treatment group. 
The participating centres are grouped by the highest to lowest recruiting country, followed by 
highest to lowest recruiting site. If centres have equal recruiting numbers, the sites are listed 
by alphabetical order. We have listed each centre by site number and name with the total 
number of patients recruited in [n], followed by names of the local principal investigator(s), 
and other significant contributors in that centre.  
Vietnam [706 patients recruited] 
Nguyen Tri Phuong Hospital [179] ((Tran Trung Thanh (PI), Le Tran Truc Mai Loan, Kieu 
Le Vu Thuy, Nguyen Van Sang, Nguyen Anh Diem Thuy, Dang Nhat Tam); 
The Peoples Hospital 115 [110] (Nguyen Huy Thang (PI), Truong Le Tuan Anh, Dam Thi 
Cam Linh, Bui Thi Quynh Chau, Ngo Thi Kim Trinh, Pham Nguyen Thanh Thai, Luong Van 
Dong, Doan Van Tan, Ma Hoa Hung, Pham Nguyen Binh, Phan Dang Loc, Dao Thi Thanh 
Nha, Nguyen Thi Bich Huong, Le Thi Cam Linh, Do Minh Chi, Huynh Quoc Huy, Nguyen 
Quoc Trung, Nguyen Thanh Thai An); 
Nghe An General Friendship Hospital [100] (Duong Dinh Chinh (PI), Kieu Van Duong, Le 
Na, Nguyen Ngoc Hoa, Le Van Binh, Nguyen Thanh Long);   
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Gia Dinh Peoples Hospital [79]  (Vo Van Tan (PI), Bui Ngoc Tram, Hoang Thi To Uyên, 
Nguyen Thi Bich Hien, Nguyen Thi Thu Ha, Lam Thuy Nga, Le Kim Khanh, Trinh Thanh 
Phuong); 
Thanh Hoa General Hospital [63] (Nguyen Hoanh Sam (PI), Le Hong Ninh, Nguyen Truong 
Giang, Doan Thi Bich, Pham Phuoc Sung, Luong Huu Duong, Mai Van Ha); 
Bach Mai Hospital [61] (Nguyen Van Chi (PI), Nguyen Doan Phuong (PI), Mai Duy Ton, 
Dao Viet Phuong, Nguyen Tien Dung, Khuong Quoc Dai, Vuong Xuan Trung, Vu Tuong 
Lan, Ngo Duc Ngoc); 
Central Military Hospital 108 [42] (Nguyen Hoang Ngoc (PI), Nguyen Van Tuyen, Le Dinh 
Toan, Dinh Hai Ha, Pham Van Cuong, Thach Thi Ngoc Khanh, Nguyen Hai Linh, Nguyen 
Thi Loan); 
Cho Ray Hospital [33] (Nguyen Anh Tai (PI), Le Van Tuan, Truong Van Luyen, Bui Chau 
Tue, Tran Van Nhat, Huynh Xuan Ngọc, Dinh Van Lap, Pham Gia An, Nguyen Tuong Vy); 
University Medical Center [22] (Nguyen Ba Thang (PI), Thai Huy, Pham Thi Ngoc Quyen, 
Dao Duy Khoa, Pham Nguyen Bao Quoc, Dang Thi Huyen Thuong, Dinh Huynh To Huong, 
Tong Mai Trang, Vu Thi Thuy, Le Tri Si, Tran Ngoc Tai, Tran Hoai Phuong); 
National Geriatric Hospital [17] (Nguyen Thanh Binh (PI), Ngo Trong Toan, Le Chung 
Thuy, Nguyen Anh Dung, Nguyen Thanh Binh, Do Phuong Vinh). 
Australia [532 patients recruited] 
Sir Charles Gairdner Hospital, WA, [93] (David Blacker (PI), Graeme Hankey, Anne 
Claxton, Lindsey Bunce, Ai Ling Tan); 
Fiona Stanley Hospital, WA, [80] (Darshan Ghia (PI), Gillian Edmonds, Nicole O’Loughlin, 
Megan Ewing, Kerri-Ann Whittaker, Lorralee Deane); 
Royal Perth Hospital, WA, [78] (Darshan Ghia (PI), Graeme Hankey, Anne Claxton); 
Calvary Health Care Bruce, ACT, [34] (Yash Gawarikar (PI), Brett Jones, Maria Lopez, 
Koushik Nagesh, Emma Siracusa);  
Royal Melbourne Hospital, VIC, [30] (Stephen Davis (PI), Amy McDonald, Jess Tsoleridis, 
Rachael McCoy, David Jackson, Gab Silver); 
St John of God Hospital Midland, WA, [25] (Tim Bates (PI), Amanda Boudville, Lynda 
Southwell); 
Liverpool Hospital, NSW, [22] (Dennis Cordato (PI), Alan J McDougall, Cecilia Cappelen-
Smith, Zeljka Calic,  Shabeel Askar, Qi Cheng, Raymond Kumar); 
Redcliffe Hospital, QLD, [18] (Richard Geraghty (PI), Maree Duroux, Megan Ratcliffe, 
Samantha Shone, Cassandra McLennan); 
Ballarat Base Hospital, VIC, [16] (Ramesh Sahathevan (PI), Casey Hair);  
6 
 
Campbelltown & Camden Hospitals, NSW, [13] (Stanley Levy (PI), Beverley Macdonald, 
Benjamin Nham, Louise Rigney, Dev Nathani, Sumana Gopinath, Vishal Patel, Abul 
Mamun,  Benjamin Trewin, Chun Phua, Ho Choong);  
Belmont Hospital, NSW, [11] (Lauren Tarrant (PI) Kerry Boyle, Luisa Hewitt, Monique 
Hourn, Amanda Masterson, Kim Oakley, Karen Ruddell, Colette Sanctuary, Kimberley 
Veitch, Jenni White); 
Blacktown Hospital, NSW, [11] (Richard Lindley (PI), Camelia Burdusel, Lina Lee, Gary 
Cheuk); 
Shoalhaven District Memorial Hospital, NSW, [11] (Jeremy Christley (PI), Tabitha Hartwell, 
Craig Davenport, Kate Hickey, Rosanna Robertson, Michelle Carr); 
Kingston Hospital, VIC, [10] (Peter New (PI) Sam Akbari, Hannah Coyle, Megan O’Neill, 
Cameron Redpath, Caroline Roberts, Marjan Tabesh, Toni Withiel); 
Osborne Park Hospital, WA, [10] ( Kapila Abeysuriya (PI), Andrew Granger (PI),  Angela 
Abraham, Chermaine Chua, Dung Do Nguyen, Vathani Surendran, Melissa Daines, David 
Shivlal, Mudassar Latif, Noreen Mughal, Patricia Morgan);  
Royal North Shore Hospital, NSW, [10] (Martin Krause (PI), Miriam Priglinger, Ehsan 
Esmaili Shandiz, Susan Day); 
Swan District Hospital, WA, [9] (Tim Bates (PI), Lay Kho); 
Rankin Park Rehab Unit, NSW, [8]( Michael Pollack (PI) Judith Dunne, Helen Baines, 
Merridie Rees, Jenni White, Monique Hourn, Luisa Hewitt, Kimberley Veitch, Aicuratiya 
Withanage, Colette Sanctuary); 
Royal Prince Alfred Hospital, NSW, [8] (Craig Anderson (PI), Candice Delcourt, Cheryl 
Carcel, Alejandra Malavera, Amy Kunchok, Elizabeth Ray); 
Calvary Mater Newcastle, NSW, [6] (Elizabeth Pepper (PI) Emily Duckett, Jenni White, 
Kimberley Veitch, Luisa Hewitt, Monique Hourn, Kerry Boyle, Sally Ormond, Colette 
Sanctuary); 
Lyell McEwin, SA, [6] (Andrew Moey (PI 2017-2019), Timothy Kleinig (PI 2016-2017), 
Vanessa Maxwell, Chantal Baldwin, Wilson Vallat, Deborah Field); 
St Vincent’s Hospital, NSW, [5] (Romesh Markus (PI), Kirsty Page, Danielle Wheelwright, 
Sam Bolitho, Steven Faux, Fix Sangvatanakul, Alexis Brown, Susan Walker, Jennifer 
Massey); 
John Hunter Hospital, NSW, [4] (Michael Pollack (PI) (Jenni White (PI), Kimberley Veitch, 
Hillary Hayes, Luisa Hewitt, Monique Hourn, Colette Sanctuary);   
Prince of Wales, NSW, [4] (Pesi Katrak (PI) (Annie Winker PI), Alessandro Zagami, Alanah 
Bailey, Sarah Mccormack, Andrew Murray, Mark Rollason, Christopher Taylor); 
7 
 
Bankstown Hospital, NSW, [3] (Fintan O’Rourke PI), Ye Min Kuang, Heike Burnet, Yvonne 
Liu, Qi Cheng, Aileen Wu); 
Caulfield Hospital, VIC, [2] (Peter New (PI), Sam Akbari, Hannah Coyle, Megan O’Neill, 
Diana Ramirez); 
Footscray & The Sunshine Hospitals, VIC, [2] (Tissa Wijeratne (PI), Sherisse Celestino, 
Essie Low, Cynthia Chen, Jennifer Bergqvist); 
Manly Hospital, NSW, [2] (Andrew Evans (PI) Queenie Leung); 
Wagga Wagga Base Hospital, NSW, [1] (Martin Jude (PI), Rachael McQueen, Katherine 
Mohr, Latitia Kernaghan); 
Flinders Medical Centre, SA, (Andrew Lee (PI), Paul Stockle, Boon Loong Tan, Sara 
Laubscher); 
Australian participating States Abbreviation Key: 
NSW = New South Wales 
QLD = Queensland 
SA = South Australia 
VIC = Victoria 
WA = Western Australia 
New Zealand [42 patients recruited] 
Hawke’s Bay Hospital [14] (John Gommans (PI), Diana Schmid, Melissa Spooner); 
Taranaki Base Hospital [14] (Bhavesh Lallu (PI), Bronwen Pepperell, John Chalissery); 
Rotorua Hospital [8] (Karim Mahawish (PI), Susan DeCaigney, Paula Broughton, Karen 
Knight, Veronica Duque); 
Wellington Hospital [6] (Harry McNaughton (PI), Jeremy Lanford, Vivian Fu, Lai-Kin 
Wong);  
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Supplementary table 1. 
Methods of patient follow-up  
Method of Follow-up  
 
Fluoxetine 
(n=642) 
Placebo 
(n=638) 
 
p-values 
(A,B) 
Day 28    
Outpatient Clinic 345 356  
Telephone 195 212  
Hospital 76 57  
Other (e.g. email, home visit) 20 11  
Missing 2 1  
Total submitted  638 637 0.0928 (0.1290B) 
    
Day 90    
Outpatient Clinic 357 360  
Telephone 233 239  
Hospital 14 6  
Other (e.g. email, home visit) 21 26  
Missing 4 0  
Total submitted  629 631 0.2848 (0.1020 B) 
    
Day 180    
Outpatient Clinic 295 321  
Telephone 300 287  
Other (e.g. email, home visit) 15 12  
Missing 2 1  
Total submitted  612 621 0.4410 (0.5879 B) 
A. P-values are based on the combined methods of follow-up (in-hospital assessment, 
outpatient clinic, telephone, home visit, and email). 
B. P-values in brackets include missing data as another category. 
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Supplementary table 2. 
Adherence to trial medication in each treatment group and overall:  
temporary and permanent cessation at each follow-up  
 
 Fluoxetine 
(n=642), 
N (%) 
Placebo 
(638), 
N (%) 
Total 
(N= 1280), 
N (%) 
p-value 
(chi-square 
test) 
Temporary 
cessation 
    
0-1 month 46/638 (7.2) 37/637(5.8) 83/1275(6.5) 0.3104 
1-3 month 34/629(5.4) 28/631(4.4) 62/1260(4.9) 0.4270 
3-6 month 19/612(3.1) 14/621(2.3) 33/1233(2.7) 0.3551 
Total* 87 71 158  
     
Permanent 
cessation 
    
0-1 month 47/638(7.4) 46/637  (7.2) 93/1275 (7.3) 0.9205 
1-3 month 34/629(5.4) 30/631(4.8) 64/1260 (5.2) 0.5987 
3-6 month 27/612(4.4) 24/621(3.9) 50/1233(4.1) 0.6296 
Total  108 100 208  
 
* Some patients reported temporary cessation of trial drug on multiple occasions. 
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Supplementary table 3. 
Compliance with trial medication (actual dosing history compared to the prescribed 
drug regimen of once daily, 7 times per week) in each treatment group and overall.* 
Time point 
Average number of 
times medication taken 
weekly 
Fluoxetine 
(n=642) 
 
Placebo 
(638) 
 
Total 
(N= 1280) 
           N (%) 
p-values 
 
1 month 
   
0.5703 
      0 times per week 26 /630 (4.1 ) 25 /631 (4.0 ) 51 /1261 (4.0 )  
      1-2 times per week 16 /630 (2.5 ) 9 /631 (1.4 ) 25 /1261 (2.0 )  
      3-4 times per week 8 /630 (1.3 ) 10 /631 (1.6 ) 18 /1261 (1.4 )  
      5-6 times per week 24 /630 (3.8 ) 17 /631 (2.7 ) 41 /1261 (3.3 )  
      7 times per week 556 /630 (88.3 ) 570 /631 (90.3 ) 1126 /1261 (89.3 )  
        Missing 8 6 14  
3 months 
   
0.9398 
      0 times per week 63 /622 (10.1 ) 62 /625 (9.9 ) 125 /1247 (10.0 )  
      1-2 times per week 6 /622 (1.0 ) 6 /625 (1.0 ) 12 /1247 (1.0 )  
      3-4 times per week 7 /622 (1.1 ) 6 /625 (1.0 ) 13 /1247 (1.0 )  
      5-6 times per week 15 /622 (2.4 ) 10 /625 (1.6 ) 25 /1247 (2.0 )  
      7 times per week 531 /622 (85.4 ) 541 /625 (86.6 ) 1072 /1247 (86.0 )  
      Missing 7 6 13  
6 months 
   
0.9190 
      0 times per week 72 /608 (11.8 ) 76 /616 (12.3 ) 148 /1224 (12.1 )  
      1-2 times per week 5 /608 (0.8 ) 5 /616 (0.8 ) 10 /1224 (0.8 )  
      3-4 times per week 6 /608 (1.0 ) 8 /616 (1.3 ) 14 /1224 (1.1 )  
      5-6 times per week 10 /608 (1.6 ) 15 /616 (2.4 ) 25 /1224 (2.0 )  
      7 times per week 515 /608 (84.7 ) 512 /616 (83.1 ) 1027 /1224 (83.9 )  
       Missing 4 5 9  
 
* Proportions were calculated based on non-missing observations. 
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Supplementary table 4.   
 
Results from the ordinal and binary analyses of the mRS  
 
 Estimate (95%CI) p-value 
Unadjusted proportional odds model: 
 
  
 
Common odds ratio (OR)  0.97 (0.79 to 1.18) 0.7354   
 
Adjusted proportional odds model* 
 
 
Common OR   0.94 (0.76 to 1.15) 0.5296  
  
Unadjusted binary logistic regressions 
  
OR: 0     vs 1-6    0.95 (0.66 to 1.36) 0.7713 
OR: 0-1  vs 2-6    1.02 (0.82 to 1.28) 0.8531 
OR: 0-2 vs 3-6     0.86 (0.67  to 1.09) 0.2069 
OR: 0-3 vs 4-6    1.04 (0.72 to 1.50) 0.8375 
OR: 0-4 vs 5-6     0.99  (0.53 to 1.83) 0.9665 
OR: 0-5 vs 6        0.99 (0.48 to 2.04) 0.9718        
 
*The covariates used for the adjustment were the same as for the primary outcome analysis, 
that is, the analysis was adjusted for baseline minimization variables including delay since 
stroke onset computer-generated prediction of 6-month outcome, presence of a motor deficit  
and aphasia. 
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Supplementary table 5.   
Sequential per-protocol analysis of the 1256 patients with mRS data at 6 months. 
Groups 
cumulatively 
excluded 
No. 
meeting 
each 
exclusion 
criteria 
Cumulative 
no. removed 
from 
analysis 
No. 
remaining 
in 
Fluoxetine 
group  
No 
remaining 
in Placebo 
group  
Common 
OR for 
mRS 
95%CI p-
value 
P-value 
(adjusted) 
None –as per 
intention to treat 
analysis 
0 0 624 632 0.97 0.79-1.18 0.7354 0.5296 
1. Ineligible-
didn’t meet all 
inclusion criteria  
4  4  621  631  0.97  0.79 -1.18  0.7354  0.5296 
2. Received no 
trial medication 
7  11  616  629  0.98  0.80 -1.20  0.8510  0.6361 
3. Received <90 
days of trial 
medication due 
to failure to 
follow trial 
procedures. 
4  15  614  627  0.98  0.80 -1.20  0.8232  0.5413 
4. Received <90 
days of trial 
medication as 
chosen by 
patient, relative, 
or doctor, but 
not for adverse 
reactions. 
30  45  598  613  0.97  0.79 -1.18  0.7412  0.4604 
5. Received <90 
days of trial 
medication due 
to suspected 
adverse reaction 
to the trial 
medication. 
68  113  571  572  0.96  0.78 -1.17  0.6660  0.4068 
6. Allocated to 
placebo but 
received an 
SSRI for > 10 
days within the 
first 90 days 
13  126  571  559  0.89  0.72 -1.10  0.2678  0.1309 
7. Allocated to 
fluoxetine but 
received an 
SSRI for > 10 
days within the 
first 90 days. 
13  139  558  559  0.86  0.69 -1.06  0.1638  0.0783 
8. Patients who 
did not complete 
at least 150 days 
of treatment 
71  210  520  526  0.90  0.72 -1.11  0.3204  0.1600 
13 
 
 
This per-protocol analysis sequentially excluded subgroups of patients who either did not 
meet our eligibility criteria or had incomplete adherence to the trial medication, and shows 
the effect of fluoxetine vs placebo on the primary outcome of the mRS at 6 months for each 
subgroup. 
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Supplementary figure 1.  
Kaplan Meier curve of time to permanent discontinuation of trial medication 
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Supplementary figure 2.  
Primary outcome by pre-specified subgroups. 
The primary efficacy outcome was shift in the modified Rankin scale score distribution (range 
0 [no symptoms] to 6 [death]) at 6 months (180 days). For subcategories, black squares 
represent point estimates (with the area of the square proportional to the number of events), 
and horizontal lines represent 95% CIs. Scores on the NIHSS range from 0 to 42, with higher 
scores indicating more severe neurological deficits. Country: Country of randomization. 
AU/NZ: Australia, New Zealand. VN: Vietnam. NIHSS: National Institutes of Health Stroke 
Scale   
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Supplementary figure 3.  
Kaplan Meier survival curve to 6 months follow-up. 
Patients who withdrew consent to be followed-up were censored at the time of withdrawal from 
the trial. 
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1280 consented and randomly assigned 
642 assigned to fluoxetine group 
 637 received fluoxetine 
 5      did not receive fluoxetine  
        (medication was lost after discharge; 
        family’s/patient’s decision to not start) 
  
638 assigned to placebo group 
 635 received placebo 
 2     did not receive placebo  
(family’s/patient’s decision to not start; 
ineligible (randomising event was a TIA)) 
 
621 submitted 180-day form 
 100  discontinued placebo 
 632  had mRS data available 
 633  had vital status known    
30 did not submit 180-day form 
 12   died 
 17 withdrew consent 
 1     too late (>14 days)    
17 did not submit 180-day form 
 11  died 
 5    withdrew consent 
 1    too late (>14 days)    
 
642 analysed 
 624 analysed for mRS  
(mRS not available for 18) 
612 submitted 180-day form 
 108  discontinued fluoxetine 
 624  had mRS data available  
 625  had vital status known   
638 analysed  
 632 analysed for mRS  
(mRS not available for 6)  
Allocation 
 
Follow-Up 
 
Analysis 
 
Enrolment 
Figure 1: AFFINITY trial profile     mRS=modified Rankin Scale 
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Figure 2. Primary outcome of the distribution of the modified Rankin Scale (mRS) scores at 6 months by treatment group  
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Supplementary figure 1. Kaplan Meier curve of time to permanent discontinuation of trial medication.
AU/NZ 284 274 0.819 [0.602,1.115]
VN 340 358 1.052 [0.797,1.39]
<=70 440 429 0.947 [0.737,1.217]
>70 184 203 0.896 [0.624,1.286]
2-8 day 475 473 0.865 [0.682,1.097]
9-15days 149 159 1.201 [0.793,1.82]
Ischaemic 534 537 0.948 [0.758,1.185]
Haemorrhagic 87 94 0.905 [0.528,1.553]
NIHSS 0-5 291 303 0.899 [0.659,1.228]
NIHSS >5 333 329 0.998 [0.756,1.317]
Yes 544 543 1.008 [0.809,1.256]
No 80 89 0.649 [0.357,1.18]
Yes 124 120 0.747 [0.467,1.196]
No 500 512 1.000 [0.796,1.258]
0-<=0.15 96 101 0.820 [0.494,1.361]
>0.15 to 1 528 531 0.948 [0.756,1.189]
Yes 14 17 0.654 [0.161,2.666]
No 610 615 0.939 [0.762,1.156]
Patient 334 324 0.857 [0.642,1.143]
Person resposible or Proxy 280 295 0.980 [0.725,1.325]
624 632 0.936 [0.762,1.15]
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Supplementary figure 2. Primary outcome by pre-specified subgroups. 
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Supplementary figure 3. Kaplan Meier survival curve to 6 months follow-up.
